Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer

Trial Profile

Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Breast cancer; Inflammatory breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
    • 28 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2019.
    • 08 Oct 2015 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top